Magenta Therapeutics logo
Magenta Therapeutics MGTA

Annual report 2025
added 03-09-2026

report update icon

Magenta Therapeutics Financial Ratios 2011-2026 | MGTA

Annual Financial Ratios Magenta Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- - -0.1 -0.0 -2.4 -5.7 -5.9 -2.2 - - - - - - -

EPS

-4.2 -2.5 -8.4 -32.6 -1.3 -1.7 -2.1 -3.1 -19.1 -65.2 - - - - -

EV (Enterprise Value)

-13.6 M -1.26 M -118 M -5.25 M 58.7 M 387 M 410 M 79.7 M -47.4 M -2.24 M - - - - -

EBITDA per Share

-4.6 -3.05 -9.33 -33.9 -1.32 -1.59 -2.19 -3.21 - - - - - - -

EV/EBITDA

-0.7 -4.8 -4.8 -1.2 - - - - - - -

PEG

- - - -0.33 -0.17 0.04 - - - - - - -

P/B

- - 0.0 0.0 1.0 3.0 3.2 0.9 - - - - - - -

P/CF

- - -0.1 -0.0 -2.9 -6.6 -7.6 -2.5 - - - - - - -

ROE %

-32.90 -24.11 -25.79 64.18 -41.20 -52.07 -54.37 -39.49 - - - - - - -

ROA %

-30.58 -22.72 -24.28 -34.26 -37.45 -46.37 -47.53 -36.56 - - - - - - -

ROCE %

-36.06 -28.90 -28.53 66.95 -43.26 -52.40 -56.29 -40.82 - - - - - - -

Current Ratio

14.1 17.4 17.0 8.8 11.0 13.3 10.6 13.9 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Magenta Therapeutics

2025-Q3 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.97 -0.88 - -0.74 -0.51 -0.54 - -3.78 -12.73 -8.1 - -8.9 -0.29 -0.39 - -0.3 -0.32 -0.36 - -0.37 -0.48 -0.51 -0.59 -0.54 -0.48 -0.44 -0.5 -0.49 -3.13 -4.53 -3.59 -3.44 -8.9 -3.59 - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-1.07 -0.97 - -0.87 -0.65 -0.69 - -4.03 -13.4 -8.77 - -9.43 -0.31 -0.4 - -0.29 -0.33 -0.38 - -0.35 -0.48 -0.53 -0.63 -0.55 -0.5 -0.48 -0.54 -0.49 -3.12 -4.52 -3.47 -3.37 -9.03 - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-32.06 -30.25 -16.05 -24.33 -25.16 -2.12 23.80 46.20 76.87 46.01 -5.51 -14.70 -46.28 -41.90 -31.08 -83.13 -125.99 -169.69 -156.14 -172.60 -174.95 -177.29 -179.64 -174.63 -159.72 -144.80 -129.89 -99.36 -144.16 -188.97 -149.49 -168.57 -84.29 - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-30.28 -28.68 -15.47 -23.14 -23.71 -33.10 -30.33 -35.08 -32.15 -29.79 -28.36 -36.81 -28.71 -36.39 -28.22 -74.57 -112.46 -151.12 -139.03 -153.42 -154.62 -155.83 -157.04 -153.25 -142.25 -131.26 -120.26 -124.41 -22.68 79.06 115.61 130.36 65.18 - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - - - - - - 23.75 47.50 34.17 -5.34 -14.96 -48.33 -43.68 -32.79 -45.56 -48.71 -53.94 -41.44 -58.89 -62.16 -61.95 -58.76 -53.52 -48.87 -44.75 -40.93 -9.32 18.71 65.64 73.40 54.01 37.35 - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

18.6 14.2 17.4 21.7 34.4 39.1 17.0 13.7 19.5 13.9 8.8 4.1 - 4.5 11.0 12.5 12.6 9.3 9.1 9.1 9.1 9.1 8.0 8.0 8.0 8.0 13.5 13.5 13.5 13.5 13.2 13.2 13.2 - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

580.6 - - 46.8 31.2 - - 11.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

580.6 - - 46.8 31.2 - - 11.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

580.6 - - 46.8 31.2 - - 11.5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Magenta Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.52 -1.26 % $ 1.05 B canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 3.22 2.88 % $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 1.81 % $ 4.36 M chinaChina
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.13 -1.67 % $ 105 M schweizSchweiz
argenx SE argenx SE
ARGX
$ 709.52 0.88 % $ 25 B niderlandNiderland
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 -5.82 % $ 8.18 B australiaAustralia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 228.5 -1.09 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.1 0.83 % $ 497 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.6 -0.45 % $ 181 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.52 1.11 % $ 213 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
BioCardia BioCardia
BCDA
$ 1.3 2.36 % $ 27.5 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.67 1.14 % $ 16.8 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 -1.32 % $ 380 M britainBritain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 92.62 2.3 % $ 27.2 B germanyGermany
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.28 2.73 % $ 1.35 B britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.16 4.5 % $ 34.9 M usaUSA